Rosemont Pharmaceuticals is a leading specialist in oral liquid medicines for people who have swallowing difficulties (dysphagia). The business has over 30 years' experience in the development, manufacture and marketing of oral liquid medicines. It offers a product range of more than 90 different drugs, all manufactured at its headquarters in Leeds.
The business was identified as non-core by its US parent Savient Pharmaceuticals Inc and a full auction process was undertaken. A £94 million MBO of the company was completed despite competition from trade acquirers. PPCF acted as lead advisor to the management team throughout the auction process.
The business has an impressive and consistent track record of turnover and profit growth. The MBO provided management with the independence to continue to build on its leading UK position, whilst developing and exploring new markets, especially in the US and continental Europe. The deal was funded by Close Brothers Private Equity and HSBC.